Global Drug Repositioning Market Strategic Research Report

Scope of the Report

The global Drug Repositioning market size is predicted to grow from US$ 31,890 million in 2025 to US$ 43,510 million in 2032; it is expected to grow at a CAGR of 4.6% from 2026 to 2032.

Drug repurposing (also called drug repositioning, reprofiling or re-tasking) is a strategy for identifying new uses for approved or investigational drugs that are outside the scope of the original medical indication. This strategy offers various advantages over developing an entirely new drug for a given indication.

The drug repositioning market is driven by the growing demand for cost-effective and time-saving drug development strategies. Traditional drug discovery can take over a decade and cost billions of dollars, with a high risk of failure during clinical trials. Repositioning, on the other hand, allows pharmaceutical companies to repurpose known drugs with existing safety and pharmacokinetic profiles, thereby accelerating time to market and reducing development risk. This approach is especially appealing for rare diseases, cancer, and neurodegenerative disorders where treatment options are limited. Additionally, advances in data mining, artificial intelligence, and systems biology have improved the ability to identify new drug-disease relationships, fueling further interest. Regulatory agencies such as the FDA and EMA also support repositioning by offering faster review pathways and incentives for orphan indications, making this strategy increasingly viable from a business perspective.

Despite its advantages, the drug repositioning market faces several challenges. One of the major issues is intellectual property protection—many repositioned drugs are off-patent, making it difficult for companies to secure exclusivity and justify investment. In cases where patent life can be extended through new formulations or uses, legal and regulatory hurdles still exist. Another challenge lies in clinical validation; while safety data may already be available, proving efficacy for a new indication still requires substantial clinical trial investment. Moreover, the lack of centralized, standardized databases for repositioning candidates limits discovery efficiency. The fragmented nature of available data—spread across academic publications, clinical trial registries, and real-world evidence—makes it hard to integrate and analyze comprehensively. Finally, collaboration between industry and academia, which is crucial for repositioning, is often hindered by misaligned goals and timelines.

This report presents a comprehensive overview of the global Drug Repositioning market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Generic Drugs
• Clinical Trial Failed Drugs

Segment by players, this report covers

• Teva
• Novartis
• Mylan
• Johnson & Johnson
• Pfizer
• Bausch Health
• GSK
• ChemRar Group
• Glenmark
• Fujifilm
• Dr. Reddy
• R-Pharma

Segment by Application

• Cardiovascular Diseases
• Mental Illness
• Cancer
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Drug Repositioning market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Cardiovascular Diseases, Mental Illness, Cancer evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact